TaiGen Biopharmaceuticals Holdings Limited(TW:4157)
NT$8.29+0.17 (+2.09%)
TW:4157
TaiGen Biopharmaceuticals Holdings Limited financials statements
NT$8.29
At close:+0.17 (+2.09%)
TaiGen Biopharmaceuticals Holdings Limited (4157) Ratios
TaiGen Biopharmaceuticals Holdings Limited Ratios
TW:4157's free cash flow for Q2 2026 was NT$-41.38M. For the 2026 fiscal year, TW:4157's free cash flow was decreased by NT$-44.00K and operating cash flow was NT$-41.33M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 13.48 | 23.57 | 23.19 | 18.50 | 13.71 |
| Quick Ratio | 12.56 | 22.64 | 22.47 | 18.20 | 13.51 |
| Cash Ratio | 1.75 | 1.61 | 7.82 | 4.74 | 4.06 |
| Solvency Ratio | 0.68 | -0.15 | 1.48 | -2.71 | 5.78 |
| Operating Cash Flow Ratio | 0.25 | -3.76 | 0.16 | -0.41 | 7.00 |
| Short-Term Operating Cash Flow Coverage | 0.60 | 0.00 | 0.00 | -7.09 | 0.00 |
| Net Current Asset Value | NT$ 1.03B | NT$ 994.13M | NT$ 999.44M | NT$ 872.26M | NT$ 1.09B |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.04 | 0.05 | 0.06 | 0.04 | 0.04 |
| Debt-to-Equity Ratio | 0.05 | 0.05 | 0.07 | 0.04 | 0.04 |
| Debt-to-Capital Ratio | 0.04 | 0.05 | 0.06 | 0.04 | 0.04 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.09 | 1.08 | 1.10 | 1.08 | 1.11 |
| Debt Service Coverage Ratio | 2.03 | -8.66 | 145.54 | -53.91 | 3393.32 |
| Interest Coverage Ratio | 41.68 | -85.74 | -153.65 | -254.27 | 3591.15 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.07 | 0.08 | 0.11 | 0.05 | 0.07 |
| Net Debt to EBITDA | -1.10 | 2.33 | -1.74 | 1.02 | -0.34 |
| Profitability Margins | |||||
| Gross Profit Margin | 86.26% | 89.29% | 90.70% | 89.69% | 99.02% |
| EBIT Margin | 26.74% | -20.88% | 117.45% | -631.83% | 67.69% |
| EBITDA Margin | 33.48% | -4.40% | 139.87% | -553.04% | 71.71% |
| Operating Profit Margin | 26.74% | -81.05% | -141.88% | -599.37% | 67.69% |
| Pretax Profit Margin | 22.14% | -21.83% | 116.53% | -634.18% | 67.67% |
| Net Profit Margin | 17.41% | -25.61% | 111.04% | -654.61% | 59.92% |
| Continuous Operations Profit Margin | 17.41% | -25.61% | 111.04% | -654.61% | 61.71% |
| Net Income Per EBT | 78.65% | 117.33% | 95.29% | 103.22% | 88.54% |
| EBT Per EBIT | 82.77% | 26.93% | -82.13% | 105.81% | 99.97% |
| Return on Assets (ROA) | 3.87% | -3.29% | 11.12% | -22.65% | 55.69% |
| Return on Equity (ROE) | 4.20% | -3.56% | 12.22% | -24.45% | 61.87% |
| Return on Capital Employed (ROCE) | 6.40% | -10.82% | -14.78% | -21.81% | 67.25% |
| Return on Invested Capital (ROIC) | 4.85% | -10.67% | -13.90% | -21.35% | 58.73% |
| Return on Tangible Assets | 3.95% | -3.32% | 11.24% | -22.89% | 56.51% |
| Earnings Yield | 0.47% | -0.47% | 1.27% | -2.06% | 7.03% |
| Efficiency Ratios | |||||
| Receivables Turnover | 20.06 | 9.19 | 3.64 | 1.35 | 4.61 |
| Payables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 0.47 | 0.38 | 0.34 | 0.24 | 0.71 |
| Fixed Asset Turnover | 14.99 | 2.23 | 1.36 | 0.64 | 16.09 |
| Asset Turnover | 0.22 | 0.13 | 0.10 | 0.03 | 0.93 |
| Working Capital Turnover Ratio | 0.25 | 0.14 | 0.13 | 0.04 | 1.80 |
| Cash Conversion Cycle | 797.43 | 1006.11 | 1189.33 | 1769.69 | 592.15 |
| Days of Sales Outstanding | 18.20 | 39.73 | 100.39 | 269.93 | 79.20 |
| Days of Inventory Outstanding | 779.23 | 966.37 | 1088.94 | 1499.76 | 512.95 |
| Days of Payables Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cycle | 797.43 | 1006.11 | 1189.33 | 1769.69 | 592.15 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 0.03 | -0.24 | 0.01 | -0.03 | 0.88 |
| Free Cash Flow Per Share | 0.02 | -0.25 | 0.00 | -0.04 | 0.86 |
| Dividend Paid and CapEx Coverage Ratio | 4.65 | -64.20 | 1.92 | -2.85 | 53.17 |
| Capital Expenditure Coverage Ratio | 4.65 | -64.20 | 1.92 | -2.85 | 53.17 |
| Operating Cash Flow Coverage Ratio | 0.43 | -2.95 | 0.10 | -0.55 | 11.77 |
| Operating Cash Flow to Sales Ratio | 0.08 | -1.15 | 0.06 | -0.59 | 0.49 |
| Free Cash Flow Yield | 0.17% | -2.14% | 0.00% | -0.25% | 5.59% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 212.36 | -212.83 | 79.21 | -48.64 | 14.26 |
| Price-to-Sales (P/S) Ratio | 36.97 | 54.53 | 87.67 | 317.56 | 8.53 |
| Price-to-Book (P/B) Ratio | 8.93 | 7.59 | 9.65 | 11.86 | 8.81 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 584.10 | -46.73 | 166075.82 | -400.42 | 17.89 |
| Price-to-Operating Cash Flow Ratio | 458.37 | -47.46 | 1447.24 | -540.94 | 17.55 |
| Price-to-Earnings Growth (PEG) Ratio | -0.98 | 1.66 | -0.50 | 0.37 | -0.05 |
| Enterprise Value Multiple | 109.33 | -1236.39 | 60.94 | -56.40 | 11.56 |
| Enterprise Value | 9.50B | 8.20B | 10.49B | 11.30B | 10.73B |
| EV to EBITDA | 109.33 | -1236.39 | 60.94 | -56.40 | 11.56 |
| EV to Sales | 36.60 | 54.43 | 85.23 | 311.92 | 8.29 |
| EV to Free Cash Flow | 578.26 | -46.65 | 161460.93 | -393.30 | 17.38 |
| EV to Operating Cash Flow | 453.79 | -47.37 | 1407.02 | -531.32 | 17.05 |
| Tangible Book Value Per Share | 1.47 | 1.49 | 1.54 | 1.34 | 1.72 |
| Shareholders’ Equity Per Share | 1.50 | 1.51 | 1.56 | 1.35 | 1.75 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.21 | -0.17 | 0.05 | -0.03 | 0.11 |
| Revenue Per Share | 0.36 | 0.21 | 0.17 | 0.05 | 1.81 |
| Net Income Per Share | 0.06 | -0.05 | 0.19 | -0.33 | 1.08 |
| Tax Burden | 0.79 | 1.17 | 0.95 | 1.03 | 0.89 |
| Interest Burden | 0.83 | 1.05 | 0.99 | 1.00 | 1.00 |
| Research & Development to Revenue | 0.37 | 1.10 | 1.52 | 6.56 | 0.22 |
| SG&A to Revenue | 0.22 | 0.60 | 0.80 | 2.00 | 0.08 |
| Stock-Based Compensation to Revenue | -0.04 | 0.22 | 0.20 | -0.14 | 0.03 |
| Income Quality | 0.36 | 4.49 | 0.05 | 0.09 | 0.72 |
Currency in TWD
